NewAmsterdam Pharma Company N.V.
NAMSNASDAQHealthcare● Active
$30.95
$-0.57(-1.81%)
Market Cap$3.6B
P/E Ratio—
52W High$42.205
52W Low$17.63
NewAmsterdam Pharma Company N.V.（NAMS）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NAMS · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M | $0.00M |
| Cost of Revenue | $0.06M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $22.44M | $45.56M | $14.09M | $102.69M | $0.00M |
| Gross Margin %(computed) | 99.74% | 100.00% | 100.00% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $141.83M | $151.41M | $159.42M | $86.74M | $28.97M |
| G&A Expenses | $106.30M | $70.45M | $37.63M | $19.51M | $4.70M |
| Total Operating Expenses | $248.13M | $221.85M | $197.06M | $106.25M | $34.98M |
| Operating Income | ($225.68M) | ($176.29M) | ($182.97M) | ($3.56M) | ($34.98M) |
| Operating Margin %(computed) | — | -386.91% | — | -3.46% | — |
| Interest Income | $27.59M | $16.88M | $10.22M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $6.80M | $0.29M | $0.41M |
| Income Before Tax | ($203.82M) | ($241.60M) | ($176.91M) | ($22.63M) | ($41.78M) |
| Income Tax Expense | $0.00M | ($0.00M) | $0.03M | $0.00M | $0.00M |
| Net Income | ($203.82M) | ($241.60M) | ($176.94M) | ($22.63M) | ($41.78M) |
| Net Margin %(computed) | -905.74% | -530.25% | — | -22.04% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.75 | $-2.56 | $-2.15 | $-1.19 | $-3.34 |
| Wtd Avg Shares | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M |
| EBITDA | ($242.32M) | ($241.49M) | ($176.86M) | ($22.34M) | ($41.37M) |
| EBITDA Margin %(computed) | — | -530.00% | — | -21.75% | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解NewAmsterdam Pharma Company N.V.
关于NewAmsterdam Pharma Company N.V.（NAMS）损益表
NewAmsterdam Pharma Company N.V.（NAMS）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，NAMS实现营收$0.02B，毛利润$0.02B（毛利率99.74%），净利润($0.20B)（净利率-905.74%）。
常见问题
NAMS · 4 问NewAmsterdam Pharma Company N.V.（NAMS）2025财年营收为$0.02B，同比down50.6%。
NAMS revenueNAMS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08